News Sentiment

NAGE sentiment intelligence

Niagen Bioscience, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.28 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-3.2% over one week, -6.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Niagen Bioscience, Inc. (NAGE) Q1 2024 Earnings Report - Results, Call & Slides

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -3.2% Price reacting lower
Trend fit Trend inactive -6.3% over four weeks
Fair value -34.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 44
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Stock Titan 10
Business Wire 7
simplywall.st 6
Investing.com 3
Investing.com Canada 3
TradingView 3
scanx.trade 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 20
Analyst action 5
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
scanx.trade Direct company coverage

Niagen Bioscience to report Q2 2026 results on August 4

Niagen Bioscience, Inc. is scheduled to announce its financial results for the second quarter ending June 30, 2026, on Tuesday, August 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a business update for the company,

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 14:40
Source
scanx.trade
Los Angeles Times Direct company coverage

Niagen Bioscience Appoints Dr. Abhijit Kale to Lead Global NAD+ Research

Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research to lead its Niagen Research Program. Dr. Kale, with over a decade of experience in aging biology and translational science, will oversee global academic and clinical research collabora

Tone
Positive 71/100
Event
Market update
Published
21 Jul 2026 14:40
Source
Los Angeles Times
MarketBeat Direct company coverage

SteelPeak Wealth LLC Makes New Investment in Niagen Bioscience, Inc. $NAGE

SteelPeak Wealth LLC has made a new investment in Niagen Bioscience, Inc. (NASDAQ:NAGE) during the first quarter, acquiring 3,373,000 shares valued at approximately $14.88 million. This new stake represents about 4.24% of the company. Other institutional investors have also adjus

Tone
Neutral 50/100
Event
Earnings
Published
17 Jul 2026 10:09
Source
MarketBeat
Business Wire Direct company coverage

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

Niagen Bioscience, Inc. has appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will lead the Global Niagen Research Program, overseeing collaborations and shaping the scientific research strategy related to NAD+ biolog

Tone
Positive 74/100
Event
Market update
Published
16 Jul 2026 21:40
Source
Business Wire
Business Wire Direct company coverage

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Niagen Bioscience has received both U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168, a novel small molecule therapy for Ataxia Telangiectasia (A-T). These designations highlight the significant

Tone
Positive 95/100
Event
Market update
Published
13 Jul 2026 12:41
Source
Business Wire
Investing.com Direct company coverage

Niagen Bioscience receives FDA, EMA designations for rare disease drug

Niagen Bioscience has received Rare Pediatric Disease Designation from the FDA and Orphan Medicinal Product Designation from the EMA for its drug candidate NB4168, which treats Ataxia Telangiectasia. This rare genetic disease currently has no FDA-approved therapies. Despite a 70%

Tone
Positive 73/100
Event
Market update
Published
13 Jul 2026 12:41
Source
Investing.com
scanx.trade Direct company coverage

Niagen Bioscience files prospectus to offer common stock up to $50M

Niagen Bioscience has filed a prospectus with the SEC to offer and sell up to $50 million in common stock. This move is part of the company's financial strategy to raise capital for future growth, operations, and expansion initiatives. The prospectus details the offering type and

Tone
Positive 67/100
Event
Market update
Published
10 Jul 2026 23:40
Source
scanx.trade
Investing.com South Africa Direct company coverage

Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com

This article reports on the filing of Form 424B5 by Niagen Bioscience Inc. on July 10, 2026. It mentions the company's stock symbol NAGE, which saw a -2.87% change. The content primarily consists of a single sentence announcing the filing, surrounded by numerous navigational link

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:10
Source
Investing.com South Africa
Stock Titan Direct company coverage

Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan

Niagen Bioscience's CFO, Pamir Ozan, acquired 4,255 shares of common stock at $2.71 per share through the company's Employee Stock Purchase Plan. This transaction increased Ozan's direct holdings to approximately 11,627 shares, with an additional 2,220 shares indirectly held by t

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:09
Source
Stock Titan
MarketBeat Direct company coverage

Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital

Freedom Capital has upgraded Niagen Bioscience (NASDAQ:NAGE) to a "strong-buy" rating, contributing to a mixed analyst sentiment that still results in an average "Buy" rating and a consensus price target of $10.50. The stock recently traded down to $3.37, below its moving average

Tone
Positive 68/100
Event
Analyst action
Published
09 Jul 2026 16:11
Source
MarketBeat
Business Wire Direct company coverage

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

Niagen Bioscience CEO Rob Fried will participate in a virtual fireside chat on July 15, 2026, to discuss the company's recently launched pharmaceutical program for rare genetic diseases and aging-related disorders. The chat will also cover Niagen Bioscience's leadership in NAD+ s

Tone
Positive 66/100
Event
Market update
Published
09 Jul 2026 12:41
Source
Business Wire
Investing.com Canada Direct company coverage

Form 4 Niagen Bioscience Inc For: 8 July By Investing.com

This article provides details about a Form 4 filing for Niagen Bioscience Inc. on July 8. It indicates that the document is published by Investing.com and was released on July 8, 2026, at 05:22 p.m. The core content highlights the Form 4 filing for NAGE, with a stock performance

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:40
Source
Investing.com Canada
Investing.com Direct company coverage

Niagen Bioscience launches drug candidate for rare disease

Niagen Bioscience has announced the launch of NB4168, a drug candidate for Ataxia Telangiectasia (A-T), a rare genetic disease with no FDA-approved therapies. Despite a recent stock decline, the company shows solid fundamentals with a 64% gross profit margin and positive earnings

Tone
Positive 71/100
Event
Earnings
Published
08 Jul 2026 13:39
Source
Investing.com
Business Wire Direct company coverage

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

Niagen Bioscience has launched a pharmaceutical program through its subsidiary, NAD Pharmaceuticals Corp., to develop therapies for accelerated aging and rare genetic diseases. The program's first drug candidate, NB4168, a proprietary NAD+ precursor derivative, will initially tar

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:39
Source
Business Wire
TradingView Direct company coverage

Enterprise value to EBIT forward of Niagen Bioscience, Inc. – NASDAQ:NAGE

The article title indicates a focus on the Enterprise Value to EBIT forward metric for Niagen Bioscience, Inc. (NASDAQ: NAGE). The content appears to be a stub or a section from a larger financial data platform, providing only the title and navigation/footer information without t

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:42
Source
TradingView
Stock Titan Direct company coverage

Niagen Bioscience (NAGE) SVP, General Counsel acquires 2,314 ESPP shares

Niagen Bioscience's SVP and General Counsel, Carlos Luis Lopez, acquired 2,314 common shares at $2.71 each through the company's Employee Stock Purchase Plan (ESPP). This transaction, exempt under SEC Rules 16b-3(c) and 16b-3(d), increased his direct ownership to 4,565 shares. Th

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:11
Source
Stock Titan
Investing.com Direct company coverage

Freedom Broker initiates Niagen Bioscience stock coverage with buy rating

Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a $9.00 price target, highlighting significant upside potential given its current trading price of $3.49 against an analyst consensus of $10-$18. The firm's investment thesis is su

Tone
Positive 80/100
Event
Analyst action
Published
06 Jul 2026 20:12
Source
Investing.com
Investing.com Canada Direct company coverage

Freedom Broker initiates Niagen Bioscience stock coverage with buy rating By Investing.com

Freedom Broker has initiated coverage on Niagen Bioscience Inc. (NASDAQ:NAGE) with a Buy rating and a price target of $9.00, citing significant upside potential from its current trading price of $3.49. The firm's investment thesis is based on secular tailwinds in the longevity ec

Tone
Positive 72/100
Event
Analyst action
Published
06 Jul 2026 19:42
Source
Investing.com Canada
TradingView Direct company coverage

Implied Volatility Surging for Niagen Bioscience Stock Options

Implied volatility for Niagen Bioscience (NAGE) stock options is surging, particularly for the August 21, 2026 $12.50 Call, indicating that the market expects significant price movement. Despite this, analysts currently rate NAGE as a Zacks Rank #3 (Hold), with recent downward re

Tone
Negative 39/100
Event
Guidance
Published
06 Jul 2026 15:41
Source
TradingView
Finviz Direct company coverage

NAGE - Niagen Bioscience Inc Options

This page provides a detailed financial overview of Niagen Bioscience Inc (NAGE), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key metrics such as P/E, EPS, insider and institutional ownership, profitabi

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 17:41
Source
Finviz
Stock Titan Direct company coverage

If You Invested $1,000 in Niagen Bioscience, Inc (NAGE)

This article analyzes the historical performance of investing $1,000 in Niagen Bioscience, Inc. (NAGE) over different periods. It provides an overview of Niagen Bioscience, detailing its focus on NAD+ science and healthy-aging research through patented ingredients like Niagen®, c

Tone
Negative 29/100
Event
Market update
Published
05 Jul 2026 05:42
Source
Stock Titan